Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma
NCT ID: NCT05063981
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
15 participants
OBSERVATIONAL
2021-11-25
2025-09-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Exclusion criteria included: current smoking; diagnosis of other chronic pulmonary diseases; coexisting chronic rhinosinusitis with nasal polyps; use of systemic corticosteroids at any dose within the 6 weeks prior to enrollment; use of immunosuppressive therapies; receipt of live attenuated vaccines within 30 days prior to enrollment; current or recent history (within the last 5 years) of malignancy, except in cases of complete remission; diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA); upper or lower respiratory tract infections within 30 days prior to signing informed consent or during the screening/run-in period; any clinically significant abnormalities identified during screening through physical examination, vital signs assessment, hematology, or clinical chemistry, which, in the opinion of the investigator, could pose a risk to patient safety or interfere with study outcomes or compliance. Additional exclusion criteria were: known immunodeficiency (primary or secondary); pregnancy; concurrent treatment with other biologics for asthma or other conditions (except for stable allergen immunotherapy, defined as an unchanged dose and regimen at screening); prior biologic therapy for asthma within 6 months before starting mepolizumab; planned surgical procedures during the study period; and participation in another interventional or post-authorization safety study.
The study lasted 24 months, including a 12-month enrollment period followed by a 12-month follow-up. Timepoints at 6 and 12 months were prespecified to capture early consolidation of treatment response and its one-year persistence, in alignment with routine follow up. Prior to inclusion, all participants underwent a clinical examination to assess eligibility. Clinical history was recorded, including age at asthma onset, smoking status, aspirin intolerance, number of exacerbations in the previous year, and asthma control level. Smoking status was recorded as never, former, or current, and current smokers were excluded. Occupational and specific environmental exposures were not systematically collected in this study. Evaluations were performed at baseline (T0), 6 (T6), and 12 months (T12) after initiation of treatment. At each timepoint, respiratory function was assessed and multiple biological matrices were collected to test markers of T2 inflammation and enable metabolomic profiling.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Severe eosinophilic asthma
Patients with severe refractory eosinophilic asthma
Mepolizumab
The effects of treatment with Mepolizumab were evaluated on clinical and laboratory markers of systemic inflammation during a 12 months follow-up period in multiple biological matrices.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mepolizumab
The effects of treatment with Mepolizumab were evaluated on clinical and laboratory markers of systemic inflammation during a 12 months follow-up period in multiple biological matrices.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age between 18 and 75 years;
* diagnosis of severe eosinophilic refractory asthma, defined as peripheral blood eosinophil count (BEC) \> 300 cells/μL and at least two documented exacerbations within the previous 12 months;
* ongoing treatment with high daily doses of inhaled corticosteroids (ICS) combined with long-acting β2-agonists (LABA), plus at least one additional controller medication for a minimum of 12 months.
Exclusion Criteria
* diagnosis of other chronic pulmonary diseases;
* coexisting chronic rhinosinusitis with nasal polyps;
* use of systemic corticosteroids at any dose within the 6 weeks prior to enrollment;
* use of immunosuppressive therapies;
* receipt of live attenuated vaccines within 30 days prior to enrollment;
* current or recent history (within the last 5 years) of malignancy, except in cases of complete remission;
* diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA);
* upper or lower respiratory tract infections within 30 days prior to signing informed consent or during the screening/run-in period;
* any clinically significant abnormalities identified during screening through physical examination, vital signs assessment, hematology, or clinical chemistry, which, in the opinion of the investigator, could pose a risk to patient safety or interfere with study outcomes or compliance.
* known immunodeficiency (primary or secondary);
* pregnancy;
* concurrent treatment with other biologics for asthma or other conditions (except for stable allergen immunotherapy, defined as an unchanged dose and regimen at screening); prior biologic therapy for asthma within 6 months before starting mepolizumab; planned surgical procedures during the study period;
* participation in another interventional or post-authorization safety study.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Palermo
OTHER
National Research Council
UNKNOWN
Istituti Clinici Scientifici Maugeri SpA
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituti Clinici Scientifici Maugeri IRCCS
Telese Terme, BN, Italy
Istituti Clinici Scientifici Maugeri IRCCS
Tradate, Varese, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Maniscalco M, Ambrosino P, Candia C, Di Stefano A, Gnemmi I, Zappa M, Ambrosino N, Visca D, Motta A. Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis. Pharmaceuticals (Basel). 2025 Nov 10;18(11):1704. doi: 10.3390/ph18111704.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Pubblication
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pascale 09/2020
Identifier Type: -
Identifier Source: org_study_id